Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker KLRS
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | Brett R R Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 1,915 | $12.9K | — | Mar 20, 2026 | Form 4 ↗ 3 days later · 1,915 shares | Form 144 ↗ |
| Feb 24, 2025 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 709 | $3,052 | — | Feb 21, 2025 | Form 4 ↗ same day · 303 shares | Form 144 ↗ |
| Feb 24, 2025 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 289 | $1,068 | — | Feb 21, 2025 | Form 4 ↗ same day · 106 shares | Form 144 ↗ |
| Feb 24, 2025 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 96 | $967 | — | Feb 21, 2025 | Form 4 ↗ 31 days later · 907 shares | Form 144 ↗ |
| Jan 24, 2025 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 129 | $1,232 | — | Jan 23, 2025 | Form 4 ↗ 31 days later · 303 shares | Form 144 ↗ |
| Jan 24, 2025 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 52 | $495 | — | Jan 23, 2025 | Form 4 ↗ 31 days later · 106 shares | Form 144 ↗ |
| Jan 24, 2025 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 36 | $341 | — | Jan 23, 2025 | Form 4 ↗ 31 days later · 96 shares | Form 144 ↗ |
| Jan 10, 2025 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 409 | $180 | — | Jan 10, 2025 | Form 4 ↗ 3 days later · 409 shares | Form 144 ↗ |
| Jan 10, 2025 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 979 | $431 | — | Jan 10, 2025 | Form 4 ↗ 3 days later · 979 shares | Form 144 ↗ |
| Jan 10, 2025 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 332 | $146 | — | Jan 10, 2025 | Form 4 ↗ 3 days later · 332 shares | Form 144 ↗ |
| Nov 19, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 3,186 | $1,735 | — | Nov 19, 2024 | Form 4 ↗ 1 day later · 3,186 shares | Form 144 ↗ |
| Nov 19, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 432 | $235 | — | Nov 19, 2024 | Form 4 ↗ 1 day later · 432 shares | Form 144 ↗ |
| Nov 19, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 554 | $302 | — | Nov 19, 2024 | Form 4 ↗ 1 day later · 554 shares | Form 144 ↗ |
| Nov 19, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 8,706 | $4,763 | — | Nov 19, 2024 | Form 4 ↗ 1 day later · 8,706 shares | Form 144 ↗ |
| Nov 5, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 2,272 | $1,965 | — | Nov 5, 2024 | Form 4 ↗ 1 day later · 2,272 shares | Form 144 ↗ |
| Nov 5, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 1,655 | $1,431 | — | Nov 5, 2024 | Form 4 ↗ 1 day later · 1,655 shares | Form 144 ↗ |
| Nov 5, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 10,609 | $9,176 | — | Nov 5, 2024 | Form 4 ↗ 1 day later · 10,609 shares | Form 144 ↗ |
| Nov 5, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 5,136 | $4,442 | — | Nov 5, 2024 | Form 4 ↗ 1 day later · 5,136 shares | Form 144 ↗ |
| Oct 22, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 486 | $373 | — | Oct 22, 2024 | Form 4 ↗ 1 day later · 965 shares | Form 144 ↗ |
| Oct 22, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 766 | $588 | — | Oct 22, 2024 | Form 4 ↗ 1 day later · 1,401 shares | Form 144 ↗ |
| Oct 22, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 1,882 | $1,445 | — | Oct 22, 2024 | Form 4 ↗ 1 day later · 3,428 shares | Form 144 ↗ |
| Oct 21, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 479 | $373 | — | Oct 21, 2024 | Form 4 ↗ 2 days later · 965 shares | Form 144 ↗ |
| Oct 21, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 1,546 | $1,204 | — | Oct 21, 2024 | Form 4 ↗ 2 days later · 3,428 shares | Form 144 ↗ |
| Oct 21, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 635 | $495 | — | Oct 21, 2024 | Form 4 ↗ 2 days later · 1,401 shares | Form 144 ↗ |
| Oct 21, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 9,752 | $7,596 | — | Oct 21, 2024 | Form 4 ↗ 2 days later · 9,752 shares | Form 144 ↗ |
| Oct 3, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 301 | $245 | — | Oct 3, 2024 | Form 4 ↗ 1 day later · 301 shares | Form 144 ↗ |
| Oct 3, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 1,493 | $1,216 | — | Oct 3, 2024 | Form 4 ↗ 1 day later · 1,493 shares | Form 144 ↗ |
| Oct 3, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 940 | $766 | — | Oct 3, 2024 | Form 4 ↗ 1 day later · 940 shares | Form 144 ↗ |
| Oct 3, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 377 | $307 | — | Oct 3, 2024 | Form 4 ↗ 1 day later · 377 shares | Form 144 ↗ |
| Aug 21, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 5,390 | $3,996 | — | Aug 20, 2024 | Form 4 ↗ 44 days later · 1,493 shares | Form 144 ↗ |
| Aug 19, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 3,091 | $2,348 | — | Aug 19, 2024 | Form 4 ↗ 46 days later · 1,493 shares | Form 144 ↗ |
| Aug 19, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 422 | $321 | — | Aug 19, 2024 | Form 4 ↗ 46 days later · 377 shares | Form 144 ↗ |
| Aug 19, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 544 | $413 | — | Aug 19, 2024 | Form 4 ↗ 46 days later · 301 shares | Form 144 ↗ |
| Aug 19, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 3,159 | $2,399 | — | Aug 19, 2024 | Form 4 ↗ 46 days later · 940 shares | Form 144 ↗ |
| Aug 6, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 1,692 | $1,243 | — | Aug 5, 2024 | Form 4 ↗ 59 days later · 301 shares | Form 144 ↗ |
| Aug 6, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 5,251 | $3,858 | — | Aug 5, 2024 | Form 4 ↗ 59 days later · 940 shares | Form 144 ↗ |
| Aug 6, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 10,847 | $7,970 | — | Aug 5, 2024 | Form 4 ↗ 59 days later · 1,493 shares | Form 144 ↗ |
| Aug 6, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 2,323 | $1,707 | — | Aug 5, 2024 | Form 4 ↗ 59 days later · 377 shares | Form 144 ↗ |
| Jul 22, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 1,858 | $1,373 | — | Jul 22, 2024 | Form 4 ↗ 74 days later · 940 shares | Form 144 ↗ |
| Jul 22, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 757 | $560 | — | Jul 22, 2024 | Form 4 ↗ 74 days later · 377 shares | Form 144 ↗ |
| Jul 22, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 481 | $356 | — | Jul 22, 2024 | Form 4 ↗ 74 days later · 301 shares | Form 144 ↗ |
| Jul 19, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 479 | $359 | — | Jul 2, 2024 | Form 4 ↗ 77 days later · 301 shares | Form 144 ↗ |
| Jul 19, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 1,542 | $1,157 | — | Jul 19, 2024 | Form 4 ↗ 77 days later · 940 shares | Form 144 ↗ |
| Jul 19, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 634 | $476 | — | Jul 19, 2024 | Form 4 ↗ 77 days later · 377 shares | Form 144 ↗ |
| Jul 19, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 9,731 | $7,299 | — | Jul 19, 2024 | Form 4 ↗ 77 days later · 1,493 shares | Form 144 ↗ |
| Jul 2, 2024 | Sinha Vikas Owner, Officer, Director | KLRS Kalaris Therapeutics, Inc. | 939 | $676 | — | Jul 2, 2024 | — | Form 144 ↗ |
| Jul 2, 2024 | Brett R. Hagen Officer | KLRS Kalaris Therapeutics, Inc. | 304 | $219 | — | Jul 2, 2024 | — | Form 144 ↗ |
| Jul 2, 2024 | Edward Miller Officer | KLRS Kalaris Therapeutics, Inc. | 379 | $273 | — | Jul 2, 2024 | — | Form 144 ↗ |
| Jul 2, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 1,489 | $1,072 | — | Jul 2, 2024 | — | Form 144 ↗ |
| May 21, 2024 | Diana Brainard Officer, Director | KLRS Kalaris Therapeutics, Inc. | 5,149 | $4,080 | — | May 21, 2024 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 11:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances